10x Genomics, Inc. (TXG)

10x Genomics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	642.82	610.79	618.73	516.41	490.49
Revenue Growth (YoY)	5.24%	-1.28%	19.81%	5.28%	64.13%
Cost of Revenue	198.94	196.3	209.41	120.39	74.09
Gross Profit	443.88	414.48	409.31	396.02	416.4
Selling, General & Admin	316.13	344.34	343.33	298.3	257.56
Research & Development	238.63	264.7	270.33	265.67	211.75
Other Operating Expenses	49.9	-	60.98	-	-0.66
Total Operating Expenses	604.67	609.04	674.64	563.97	468.65
Operating Income	-60.99	-194.56	-265.33	-167.94	-52.25
Interest Income	20.05	18.93	16.89	6.65	0.21
Interest Expense	-	-0	-0.03	-0.48	-0.87
Other Non-Operating Income (Expense)	1.03	-2.07	-0.29	-0.2	-0.8
Total Non-Operating Income (Expense)	21.08	16.86	16.57	5.97	-1.46
Pretax Income	-39.91	-177.7	-248.76	-161.97	-53.72
Provision for Income Taxes	3.64	4.93	6.34	4.03	4.51
Net Income	-43.54	-182.63	-255.1	-166	-58.22
Net Income to Common	-43.54	-182.63	-255.1	-166	-58.22
Shares Outstanding (Basic)	125	120	117	114	110
Shares Outstanding (Diluted)	125	120	117	114	110
Shares Change (YoY)	3.57%	2.80%	2.90%	3.18%	9.09%
EPS (Basic)	-0.35	-1.52	-2.18	-1.46	-0.53
EPS (Diluted)	-0.35	-1.52	-2.18	-1.46	-0.53
Free Cash Flow	130.12	-5.73	-63.8	-165.27	-122.65
Free Cash Flow Per Share	1.04	-0.05	-0.54	-1.45	-1.11
Gross Margin	69.05%	67.86%	66.15%	76.69%	84.89%
Operating Margin	-9.49%	-31.85%	-42.88%	-32.52%	-10.65%
Profit Margin	-6.77%	-29.90%	-41.23%	-32.15%	-11.87%
FCF Margin	20.24%	-0.94%	-10.31%	-32.00%	-25.01%
EBITDA	-17.17	-150.85	-221.71	-134.94	-24
EBITDA Margin	-2.67%	-24.70%	-35.83%	-26.13%	-4.89%
EBIT	-60.99	-194.56	-265.33	-167.94	-52.25
EBIT Margin	-9.49%	-31.85%	-42.88%	-32.52%	-10.65%
Effective Tax Rate	-9.11%	-2.77%	-2.55%	-2.49%	-8.39%

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q